EcoVadis Gold rating validates Ontex’s business sustainability commitments and performance for second year in a row Aalst, Belgium, February 19, 2026 – Ontex Group NV [EURONEXT: ONTEX], a leading international developer and producer of personal care solutions, announces that it has been awarded a Gold rating by EcoVadis for the second consecutive year. EcoVadis, a global leader in business sustainability assessments, awarded Ontex a higher total score year on year, placing the company in the top 3% of companies assessed globally. The recognition reflects the solid foundations Ontex has bu...
EcoVadis goud-beoordeling bevestigt voor tweede jaar op rij duurzaamheidsengagement en -prestaties van Ontex Aalst, België, 19 februari 2026 – Ontex Group NV [EURONEXT: ONTEX], een toonaangevende ontwikkelaar en producent van persoonlijke verzorgingsproducten, heeft het tweede jaar op rij een gouden medaille van EcoVadis ontvangen. EcoVadis, wereldwijd toonaangevend in duurzaamheidsbeoordelingen van bedrijven, kende Ontex een hogere totaalscore toe dan vorig jaar. Ontex behoort daarmee vandaag tot de top 3% van de wereldwijd beoordeelde bedrijven. De erkenning weerspiegelt de solide funda...
Ontex has released weak FY 2025 results. The company downgraded its guidance twice in the year, due to soft demand amid weak consumer sentiment, high promotional activity from A brands and supply-chain constraints, as well as increases in raw-material costs. Meanwhile, H2 was more challenging than management's initial expectations. Looking ahead, Ontex anticipates that market conditions will remain soft. That said, management is optimistic that performance will improve gradually through the year...
GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales Ipsen reported US$88M of Iqirvo® net sales in PBC for 4Q25, bringing 2025 sales to US$208M, triggering the first commercial milestone payment to GENFIT ahead of schedule1Ipsen confirmed its commitment to launch a Phase 3 in PSC, creating a new avenue for potential future upside for GENFITGENFIT’s CCA Phase 1b study progressing as planned: New dose-escalation cohort fully enrolled with no dose-limiting toxicities reported at the 21-day timepoint Phase 1b data readout ...
GENFIT va recevoir un paiement d’étape de 20 M$ suite au dépassement du seuil des 200 M$ de ventes nettes d’Iqirvo® par Ipsen dès sa première année complète de commercialisation Ventes nettes d’Iqirvo® dans la PBC par Ipsen atteignant 88 M$ au 4T25, portant le total annuel pour 2025 à 208 M$, déclenchant le premier paiement d’étape1 commercial pour GENFIT plus tôt que prévu Confirmation par Ipsen du lancement d’une Phase 3 dans la PSC, ouvrant une nouvelle opportunité de création de valeur potentielle pour GENFITL’étude de Phase 1b de GENFIT dans le CCA progresse comme prévu : Nouvelle coho...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.